Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufact… Read more
Gufic Biosciences Limited (GUFICBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.094x
Based on the latest financial reports, Gufic Biosciences Limited (GUFICBIO) has a cash flow conversion efficiency ratio of 0.094x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹591.15 Million) by net assets (₹6.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gufic Biosciences Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Gufic Biosciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Gufic Biosciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gufic Biosciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tiziana Life Sciences Ltd
NASDAQ:TLSA
|
-0.742x |
|
Accsys Technologies PLC
PINK:ACSYF
|
0.058x |
|
Pro-Dex Inc
NASDAQ:PDEX
|
0.086x |
|
Cognor S.A.
WAR:COG
|
0.055x |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
0.386x |
|
Sonaecom S.G.P.S. S.A
STU:XOA1
|
-0.002x |
|
Quirin Privatbank AG
F:QB7
|
N/A |
|
SAVANNAH RES PLC LS -01
F:SAV
|
N/A |
Annual Cash Flow Conversion Efficiency for Gufic Biosciences Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Gufic Biosciences Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹6.01 Billion | ₹1.03 Billion | 0.171x | +1319.29% |
| 2024-03-31 | ₹5.33 Billion | ₹-74.57 Million | -0.014x | +81.68% |
| 2023-03-31 | ₹3.48 Billion | ₹-265.87 Million | -0.076x | -119.70% |
| 2022-03-31 | ₹2.69 Billion | ₹1.04 Billion | 0.388x | -24.43% |
| 2021-03-31 | ₹1.73 Billion | ₹890.65 Million | 0.514x | +45.34% |
| 2020-03-31 | ₹1.29 Billion | ₹456.94 Million | 0.353x | +411.25% |
| 2019-03-31 | ₹753.48 Million | ₹52.07 Million | 0.069x | +176.74% |
| 2018-03-31 | ₹535.16 Million | ₹-48.20 Million | -0.090x | +18.60% |
| 2017-03-31 | ₹373.27 Million | ₹-41.30 Million | -0.111x | +12.98% |
| 2016-03-31 | ₹339.59 Million | ₹-43.17 Million | -0.127x | -130.89% |
| 2015-03-31 | ₹271.00 Million | ₹111.53 Million | 0.412x | -0.73% |
| 2014-03-31 | ₹262.09 Million | ₹108.66 Million | 0.415x | +76.61% |
| 2013-03-31 | ₹223.94 Million | ₹52.57 Million | 0.235x | -11.30% |
| 2012-03-31 | ₹195.14 Million | ₹51.65 Million | 0.265x | +439.33% |
| 2011-03-31 | ₹184.37 Million | ₹9.05 Million | 0.049x | -77.72% |
| 2010-03-31 | ₹174.24 Million | ₹38.37 Million | 0.220x | -29.96% |
| 2009-03-31 | ₹166.47 Million | ₹52.34 Million | 0.314x | +911.91% |
| 2008-03-31 | ₹162.63 Million | ₹5.05 Million | 0.031x | -89.80% |
| 2007-03-31 | ₹158.38 Million | ₹48.24 Million | 0.305x | -16.50% |
| 2006-03-31 | ₹155.93 Million | ₹56.87 Million | 0.365x | -- |